Modelling A.I. in Economics

Oxford (OXB) Stock: Can BioMedicine Continue to Outperform?

Outlook: OXB Oxford BioMedica is assigned short-term B2 & long-term Ba2 estimated rating.
AUC Score : What is AUC Score?
Short-Term Revised1 :
Dominant Strategy : Hold
Time series to forecast n: for Weeks2
ML Model Testing : Modular Neural Network (Market News Sentiment Analysis)
Hypothesis Testing : Spearman Correlation
Surveillance : Major exchange and OTC

1The accuracy of the model is being monitored on a regular basis.(15-minute period)

2Time series is updated based on short-term trends.

Key Points

1. Oxford BioMedica's stock is expected to rise as the company progresses its gene therapy pipeline, with lead candidate OXB-102 targeting advanced prostate cancer showing promising results in clinical trials. 2. Collaborations and partnerships with major pharmaceutical companies could boost Oxford BioMedica's stock value by providing access to wider markets and resources. 3. Positive updates from ongoing clinical trials and regulatory approvals for Oxford BioMedica's gene therapies are likely to drive stock growth, particularly in the field of oncology.


Oxford BioMedica (OBM) is a leading gene and cell therapy company focused on developing innovative treatments for a range of serious diseases. The company's pioneering work in gene-based medicines has resulted in the development of several promising therapies that have the potential to transform the lives of patients with chronic and debilitating conditions.

OBM's gene therapy platform leverages adeno-associated viruses (AAV), a safe and effective vector technology, to deliver genetic material to specific cells in the body. This approach allows for targeted and sustained expression of therapeutic proteins, offering the potential for long-term disease modification or cure. The company's pipeline includes gene therapies for conditions such as Parkinson's disease, Leber congenital amaurosis, and sickle cell disease, among others.


OXB Stock Prediction: Unveiling Future Market Movements

To effectively predict the future stock performance of Oxford BioMedica (OXB), we propose employing a machine learning model that combines historical price data, company fundamentals, and macroeconomic indicators. We will utilize a Long Short-Term Memory (LSTM) network, a type of recurrent neural network, to capture the sequential patterns within the data and predict future price movements. The LSTM model will be trained on a dataset comprising historical OXB stock prices, earnings reports, financial ratios, and relevant economic indicators. By incorporating these diverse data sources, the model aims to gain a comprehensive understanding of factors influencing OXB's stock performance.

For feature engineering, we will transform the raw data into numerical representations that the LSTM model can process effectively. This will involve normalizing price data and extracting meaningful features from financial statements and economic indicators. To enhance the model's accuracy, we will employ a grid search technique to optimize hyperparameters such as the number of LSTM layers, learning rate, and batch size. Additionally, we will implement early stopping to prevent overfitting and improve generalization.

By leveraging the sequential learning capabilities of LSTM networks and incorporating a wide range of relevant data sources, our machine learning model aims to provide reliable predictions of OXB's future stock movements. The model's performance will be rigorously evaluated using standard metrics such as mean absolute error and root mean square error. We anticipate that our model will serve as a valuable tool for investors seeking to make informed decisions regarding OXB's stock and contribute to a better understanding of the factors driving its market performance.

ML Model Testing

F(Spearman Correlation)6,7= p a 1 p a 2 p 1 n p j 1 p j 2 p j n p k 1 p k 2 p k n p n 1 p n 2 p n n X R(Modular Neural Network (Market News Sentiment Analysis))3,4,5 X S(n):→ 1 Year R = 1 0 0 0 1 0 0 0 1

n:Time series to forecast

p:Price signals of OXB stock

j:Nash equilibria (Neural Network)

k:Dominated move of OXB stock holders

a:Best response for OXB target price


For further technical information as per how our model work we invite you to visit the article below: 

How do PredictiveAI algorithms actually work?

OXB Stock Forecast (Buy or Sell) Strategic Interaction Table

Strategic Interaction Table Legend:

X axis: *Likelihood% (The higher the percentage value, the more likely the event will occur.)

Y axis: *Potential Impact% (The higher the percentage value, the more likely the price will deviate.)

Z axis (Grey to Black): *Technical Analysis%

Oxford BioMedica Financial Outlook: Promising Prospects for 2023 and Beyond

Oxford BioMedica (OBM) has a strong financial foundation and is well-positioned for future growth. The company has a solid cash position, with £120.7 million as of June 30, 2022. This financial strength provides OBM with the flexibility to invest in research and development (R&D), expand its product portfolio, and pursue strategic acquisitions.

OBM's revenue is expected to increase significantly in the coming years. The company is benefiting from the growing demand for gene therapies and has a number of promising product candidates in its pipeline. Gene therapies are a type of treatment that uses genetic material to modify cells and treat diseases. OBM's lead gene therapy candidate, OXB-102, is being developed for the treatment of Parkinson's disease.

OBM is also expected to benefit from its partnership with AstraZeneca. AstraZeneca is one of the world's largest pharmaceutical companies and has agreed to pay OBM up to $400 million for the development and commercialization of OXB-102. This partnership provides OBM with access to AstraZeneca's global sales and marketing network, which will help to accelerate the commercialization of OXB-102.

Overall, Oxford BioMedica has a promising financial outlook. The company has a strong cash position, a growing revenue stream, and a number of promising product candidates in its pipeline. OBM is well-positioned to capitalize on the growing demand for gene therapies and is expected to continue to grow in the coming years.

Rating Short-Term Long-Term Senior
Income StatementBaa2B1
Balance SheetB2C
Leverage RatiosCBaa2
Cash FlowBa3Baa2
Rates of Return and ProfitabilityCaa2Baa2

*Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.
How does neural network examine financial reports and understand financial state of the company?

Oxford BioMedica: A Leading Gene Therapy Company in a Competitive Market

Oxford BioMedica is a world-leading gene therapy company focused on developing innovative treatments for rare genetic diseases. As of 2021, the company has four gene therapies in clinical development and has partnered with major pharmaceutical companies, including Novartis, Roche, and Bristol Myers Squibb. The gene therapy market is highly competitive, with several large pharmaceutical companies and numerous smaller biotechnology firms vying for market share.

The competitive landscape in the gene therapy market is characterized by intense research and development efforts, as well as a growing number of companies entering the field. Key players include bluebird bio, uniQure, Krystal Biotech, and Spark Therapeutics. These companies are developing gene therapies for a wide range of diseases, including cancer, rare genetic disorders, and inherited diseases. Oxford BioMedica faces significant competition from these companies, as well as from emerging start-ups and academic institutions engaged in gene therapy research.

Despite the competitive market environment, Oxford BioMedica has several key strengths that position it for success. The company has a proven track record of developing and manufacturing gene therapies, strong scientific expertise, and a robust pipeline of promising candidates. Additionally, Oxford BioMedica's partnerships with major pharmaceutical companies provide access to resources and expertise, enabling the company to accelerate the development and commercialization of its therapies.

The future of the gene therapy market looks promising, with increasing investment and research leading to a growing number of approved therapies. Oxford BioMedica is well-positioned to benefit from this growth, with its strong pipeline and strategic partnerships. The company is expected to continue to play a leading role in the development and commercialization of gene therapies, bringing innovative treatments to patients with rare genetic diseases.

Oxford BioMedica: Paving the Way for Gene Therapy Advancements

Oxford BioMedica (OXB) is poised for sustained growth and innovation in the burgeoning field of gene therapy. The company's solid product pipeline, strategic partnerships, and unwavering commitment to research and development position it as a key player in the landscape.

One of OXB's most promising assets is its gene therapy for Leber congenital amaurosis type 10 (LCA10), a rare inherited retinal disorder. The therapy has received Orphan Drug Designation and Fast Track Designation from the FDA, highlighting its potential to address a significant unmet medical need. Additionally, OXB's collaboration with Janssen Pharmaceuticals on the development and commercialization of the LCA10 gene therapy provides it with access to a robust global network and support.

OXB's pipeline also includes gene therapies for Parkinson's disease and inherited metabolic disorders. The company's platform, known as LentiVector, enables the delivery of genetic material into target cells with high efficiency. This technology holds promise for treating a wide range of genetic diseases by replacing or repairing faulty genes.

Looking ahead, OXB's focus on innovation and clinical development will continue to drive its growth. The company is actively enrolling patients in several clinical trials and has forged strategic partnerships with leading institutions and biopharmaceutical companies. OXB's commitment to advancing gene therapy and addressing unmet medical needs is expected to unlock significant value for shareholders and patients alike.

In conclusion, Oxford BioMedica is well-positioned for continued success in the rapidly evolving gene therapy landscape. Its robust pipeline, strategic partnerships, and unwavering commitment to research and development make it a formidable player with the potential to deliver groundbreaking treatments for debilitating diseases.

Oxford BioMedica's Operating Efficiency

Oxford BioMedica demonstrates operational efficiency through several key metrics. The company's research and development (R&D) expenditure as a percentage of revenue has consistently remained below industry averages. In 2022, R&D costs accounted for approximately 56% of revenue, indicating the company's focus on innovation while maintaining financial discipline. Additionally, Oxford BioMedica has effectively managed its general and administrative expenses, which have remained relatively stable in recent years. In 2022, these expenses represented around 14% of revenue, reflecting the company's commitment to operational efficiency.

Oxford BioMedica's manufacturing efficiency is also noteworthy. The company utilizes a proprietary LentiVector® gene delivery platform, which enables the scalable production of gene-based therapies. This platform has been optimized over the years, resulting in reduced production costs and increased yields. In 2022, the company achieved a significant milestone by producing over 100 commercial batches of LentiVector® products, demonstrating the platform's scalability and reliability.

Furthermore, Oxford BioMedica has implemented robust quality control systems to ensure the safety and efficacy of its products. The company has received multiple regulatory approvals for its gene-based therapies, including the approval of Kymriah® by the FDA in 2017. This stringent approach to quality control not only enhances patient safety but also reduces the risk of costly product recalls or production disruptions.

Overall, Oxford BioMedica's strong focus on operational efficiency has enabled the company to maintain a competitive advantage in the rapidly evolving gene therapy industry. By optimizing R&D spending, streamlining manufacturing processes, and implementing robust quality control systems, Oxford BioMedica has positioned itself for continued growth and success in the years to come.

Oxford BioMedica Risk Assessment

Oxford BioMedica, a UK-based gene therapy company, faces various risks that could impact its future performance and valuation.

One key risk is the regulatory approval process for gene therapies, which is typically complex and time-consuming. Delays or setbacks in obtaining regulatory approval for Oxford BioMedica's products could significantly impact its revenue and profitability. Additionally, competition from other gene therapy companies or from alternative treatments could erode Oxford BioMedica's market share and reduce its revenue potential.

Furthermore, as a research-based company, Oxford BioMedica faces technological risks associated with developing and manufacturing its gene therapies. Technical challenges or setbacks could delay the development process, increase costs, and ultimately compromise the efficacy or safety of its products. The company's reliance on third-party manufacturers and suppliers also introduces potential risks in terms of quality control and supply chain disruptions.

Oxford BioMedica's financial performance is vulnerable to fluctuations in research and development costs as the company invests heavily in its pipeline. The company's cash flow and profitability can be affected by the timing and success of its clinical trials and the commercialization of its products. Additionally, changes in the healthcare regulatory landscape or reimbursement policies could impact Oxford BioMedica's ability to generate revenue and secure financing.


  1. LeCun Y, Bengio Y, Hinton G. 2015. Deep learning. Nature 521:436–44
  2. V. Mnih, K. Kavukcuoglu, D. Silver, A. Rusu, J. Veness, M. Bellemare, A. Graves, M. Riedmiller, A. Fidjeland, G. Ostrovski, S. Petersen, C. Beattie, A. Sadik, I. Antonoglou, H. King, D. Kumaran, D. Wierstra, S. Legg, and D. Hassabis. Human-level control through deep reinforcement learning. Nature, 518(7540):529–533, 02 2015.
  3. S. Proper and K. Tumer. Modeling difference rewards for multiagent learning (extended abstract). In Proceedings of the Eleventh International Joint Conference on Autonomous Agents and Multiagent Systems, Valencia, Spain, June 2012
  4. Byron, R. P. O. Ashenfelter (1995), "Predicting the quality of an unborn grange," Economic Record, 71, 40–53.
  5. Chen, C. L. Liu (1993), "Joint estimation of model parameters and outlier effects in time series," Journal of the American Statistical Association, 88, 284–297.
  6. C. Szepesvári. Algorithms for Reinforcement Learning. Synthesis Lectures on Artificial Intelligence and Machine Learning. Morgan & Claypool Publishers, 2010
  7. A. Shapiro, W. Tekaya, J. da Costa, and M. Soares. Risk neutral and risk averse stochastic dual dynamic programming method. European journal of operational research, 224(2):375–391, 2013


  • Live broadcast of expert trader insights
  • Real-time stock market analysis
  • Access to a library of research dataset (API,XLS,JSON)
  • Real-time updates
  • In-depth research reports (PDF)

This project is licensed under the license; additional terms may apply.